VALIDATION OF A PANEL OF GENETIC MARKERS (CRS7) IN PREDICTING CIRRHOSIS, FIBROSIS PROGRESSION (FP) AND CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) IN THE HALT-C TRIAL

被引：0
|
作者：
Curto, Teresa M. [1 ]
Lok, Anna S. [2 ]
Lagier, Robert J. [4 ]
Rowland, Charles M. [4 ]
Sninsky, John [4 ]
Everhart, James E. [3 ]
机构：
[1] New England Res Inst, Watertown, MA 02172 USA
[2] Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI USA
[3] NIDDK, Bethesda, MD USA
[4] Celera, Alameda, CA USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1620
引用
收藏
页码：1054A / 1054A
页数：1
相关论文
共 25 条
  • [21] Association of IL28B Genotype With Fibrosis Progression and Clinical Outcomes in Patients With Chronic Hepatitis C: A Longitudinal Analysis
    Noureddin, Mazen
    Wright, Elizabeth C.
    Alter, Harvey J.
    Clark, Shauna
    Thomas, Emmanuel
    Chen, Richard
    Zhao, Xiongce
    Conry-Cantilena, Cathy
    Kleiner, David E.
    Liang, T. Jake
    Ghany, Marc G.
    HEPATOLOGY, 2013, 58 (05) : 1548 - 1557
  • [22] Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C
    Konerman, Monica A.
    Lu, Dongxia
    Zhang, Yiwei
    Thomson, Mary
    Zhu, Ji
    Verma, Aashesh
    Liu, Doting
    Talaat, Nizar
    Balis, Ulysses
    Higgins, Peter D. R.
    Lok, Anna S. F.
    Waljee, Akbar K.
    PLOS ONE, 2017, 12 (11):
  • [23] ENHANCED LIVER FIBROSIS (ELF) TEST PERFORMS BETTER THAN HISTOLOGICAL PARAMETERS IN PREDICTING CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED FIBROSIS DUE TO CHRONIC HEPATITIS C INFECTION
    Dolman, G. E.
    Zaitoun, A.
    Irving, W. L.
    Guha, N. I.
    GUT, 2014, 63 : A245 - A245
  • [24] ENHANCED LIVER FIBROSIS (ELF) TEST PERFORMS BETTER THAN HISTOLOGICAL PARAMETERS IN PREDICTING CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED FIBROSIS DUE TO CHRONIC HEPATITIS C INFECTION
    Dolman, G. E.
    Zaitoun, A. M.
    Irving, W. L.
    Guha, I. N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S412 - S412
  • [25] Clinical utility of alpha fetoprotein (AFP) L3 and des-gamma carboxy prothrombin (DCP) in patients (pts) with hepatitis C (HCV) and advanced fibrosis at risk for hepatocellular carcinoma (HCC): Results from the lead in phase of the HALT-C trial.
    Sterling, RK
    Lok, AS
    Seeff, LB
    Hoefs, JC
    Wright, EC
    GASTROENTEROLOGY, 2005, 128 (04) : A762 - A762
123